What is STERIS's AST — R&D?

STERIS (STE) reported AST — R&D of $800K in Q1 2026.

How has STERIS's AST — R&D changed year-over-year?

STERIS's AST — R&D decreased by 27.3% year-over-year, from $1.1M to $800K.

What is the long-term trend for STERIS's AST — R&D?

Over 3 years (2023 to 2026), STERIS's AST — R&D has grown at a -13.4% compound annual growth rate (CAGR), from $4.93M to $3.2M.

What does AST — R&D mean?

Reflects investments in new sterilization technologies, process improvements, and regulatory compliance innovations. It indicates the company's commitment to maintaining its competitive advantage in sterilization efficacy and safety standards.

STERIS STE AST — R&D

Other segment segments

Healthcare Segment

$25.3M+6.8%

Life Sciences:

$2.8M+16.7%

Similar metrics at other companies

NAG

NAGEAnalytical Reference Standards and Services segment — R&D

$0—

INVTechnology — R&D

$3.99M-8.2%

KLICAdvanced Solutions — R&D

$15.34M+26.4%

DRSASC — Total company-funded independent research and development

$24M+4.3%

KLICAPS — R&D

$2.92M+12.1%

PTH

PTHSResearch and Development operations — Total Assets

$1.1M—

Other financials

Income statement

See full

Revenue$1.6B+7.3%

Gross profit$697.2M+8.8%

Operating income$316.8M+46.6%

Net income$220.2M+51.2%

EPS (diluted)$2.24+52.4%

Balance sheet

See full

Cash & equivalents$439.6M+156%

Total debt$2.1B-10.3%

Total equity$7.2B+8.8%

Total assets$10.7B+5.8%

Cash flow

See full

Operating cash flow$335.4M+28.6%

CapEx$90.2M+27.2%

Free cash flow$245.2M+29.1%

Valuation

See full

Market cap$20.52B-9.4%

Enterprise value$22.17B-8.8%

P/E26.2×-8.8×

P/S3.5×-0.6×

Profitability

See full

Gross margin44.2%+0.2pp

Operating margin18.6%+2.7pp

Net margin13.2%+1.9pp

FCF margin16.4%+2.1pp

Returns & leverage

See full

Return on equity11.3%+1.8pp

Debt / equity0.3×-0.1×

Current ratio2.1×+0.1×

Where this comes from

Reported directly by STERIS in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: STERIS’s 10-K, filed May 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about STERIS's ast — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is STERIS's AST — R&D?: STERIS (STE) reported AST — R&D of $800K in Q1 2026.
How has STERIS's AST — R&D changed year-over-year?: STERIS's AST — R&D decreased by 27.3% year-over-year, from $1.1M to $800K.
What is the long-term trend for STERIS's AST — R&D?: Over 3 years (2023 to 2026), STERIS's AST — R&D has grown at a -13.4% compound annual growth rate (CAGR), from $4.93M to $3.2M.
What does AST — R&D mean?: Reflects investments in new sterilization technologies, process improvements, and regulatory compliance innovations. It indicates the company's commitment to maintaining its competitive advantage in sterilization efficacy and safety standards.